These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2062794)

  • 1. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats.
    Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L
    Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rat.
    Monti E; Piccinini F; Villani F; Favalli L
    Cancer Chemother Pharmacol; 1986; 18(3):289-91. PubMed ID: 3802385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of calcium inhibitors and calcium mobilizers on doxorubicin accumulation in rat myocardial tissue.
    Monti E; Paracchini L; Piccinini F; Rozza A; Villani F
    Pharmacol Res Commun; 1988 May; 20(5):369-76. PubMed ID: 3420140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
    Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
    Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
    G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin.
    Danesi R; Bernardini N; Agen C; Costa M; Macchiarini P; Della Torre P; Del Tacca M
    Toxicology; 1991; 70(2):243-53. PubMed ID: 1763418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
    Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
    Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.
    Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M
    Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin.
    Villani F; Galimberti M; Monti E; Piccinini F; Lanza E; Rozza A; Favalli L; Poggi P; Zunino F
    Free Radic Res Commun; 1990; 11(1-3):145-51. PubMed ID: 2074045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat.
    Jensen RA
    J Pharmacol Exp Ther; 1986 Jan; 236(1):197-203. PubMed ID: 3941392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.
    Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P
    Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
    Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
    Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat.
    Villani F; Monti E; Piccinini F; Favalli L; Rozza Dionigi A; Lanza E; Poggi P
    Anticancer Res; 1988; 8(4):659-63. PubMed ID: 3178155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity induced by doxorubicin in vivo: protective activity of the spin trap alpha-phenyl-tert-butyl nitrone.
    Jotti A; Paracchini L; Perletti G; Piccinini F
    Pharmacol Res; 1992 Sep; 26(2):143-50. PubMed ID: 1409255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin II on the antitumor activity and cardiotoxicity of doxorubicin.
    Monti E; Paracchini L; Piccinini F; Rossi C; Formelli F
    Cancer Lett; 1990 Apr; 50(1):79-85. PubMed ID: 2353985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects.
    Jensen RA; Acton EM; Peters JH
    J Cardiovasc Pharmacol; 1984; 6(1):186-200. PubMed ID: 6199603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erdosteine prevents doxorubicin-induced cardiotoxicity in rats.
    Yagmurca M; Fadillioglu E; Erdogan H; Ucar M; Sogut S; Irmak MK
    Pharmacol Res; 2003 Oct; 48(4):377-82. PubMed ID: 12902208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
    Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity.
    Perletti G; Monti E; Paracchini L; Piccinini F
    Arch Int Pharmacodyn Ther; 1989; 302():280-9. PubMed ID: 2636823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia as a risk factor for doxorubicin-induced cardiotoxicity: a NMR evaluation.
    Bradamante S; Monti E; Paracchini L; Perletti G
    Biochem Biophys Res Commun; 1989 Sep; 163(2):682-8. PubMed ID: 2783116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.